The estimated Net Worth of Robert R. Jr. Banks is at least $132 Thousand dollars as of 14 May 2024. Robert Banks owns over 50,000 units of Nephros Inc stock worth over $131,950 and over the last few years Robert sold NEPH stock worth over $0.
Robert has made over 3 trades of the Nephros Inc stock since 2023, according to the Form 4 filled with the SEC. Most recently Robert bought 50,000 units of NEPH stock worth $112,000 on 14 May 2024.
The largest trade Robert's ever made was buying 50,000 units of Nephros Inc stock on 14 May 2024 worth over $112,000. On average, Robert trades about 23,333 units every 91 days since 2023. As of 14 May 2024 Robert still owns at least 70,000 units of Nephros Inc stock.
You can see the complete history of Robert Banks stock trades at the bottom of the page.
Robert's mailing address filed with the SEC is 380, Lackawanna Place, Academy Heights, South Orange, Essex County, New Jersey, 07079, United States.
Over the last 6 years, insiders at Nephros Inc have traded over $0 worth of Nephros Inc stock and bought 188,822 units worth $443,998 . The most active insiders traders include Capital Lp Wexford Gp Llcda..., Robert R. Jr. Banks, and Andrew Astor. On average, Nephros Inc executives and independent directors trade stock every 70 days with the average trade being worth of $15,834. The most recent stock trade was executed by Arthur H Amron on 28 May 2024, trading 5,000 units of NEPH stock currently worth $11,200.
nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters. nephros filters capture contaminants as small as 5 nanometers in size; they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites, and endotoxins. nephros filters use a proprietary hollow fiber technology; the hollow fiber design enables the filters to optimize the three elements critical to filter performance: • filtration – as low as 5 nanometers • flow rate – minimal disruption • filter life – up to 12 months nephros was founded in 1997, by healthcare professionals affiliated with columbia university medical center, initially to address the needs of chronic renal failure patients. the company has developed an alternative to current hemodialysis therapy known as mid-dilution hemodiafiltration (mid-hdf). nephros’ proprietary blood purification technologies enable mid-hdf to be offered to chronic renal failure patients. nephros mid-dilution fil
Nephros Inc executives and other stock owners filed with the SEC include: